Precision oncology platform for dogs using genomic testing to identify targeted cancer therapies beyond chemo and radiation.
FidoCure uses genomic testing and tumor profiling to identify cancer-driving mutations in dogs, then recommends personalized targeted therapeutic options. Developed by One Health Company, the platform is used by veterinarians and oncologists and has built the largest proprietary canine cancer dataset in the world from thousands of treated dogs. FidoCure has sequenced and treated dogs across thousands of clinics with near-100% oncologist adoption. FidoCure is a product of FidoCure®.